VIA
VIR icon

Vident Investment Advisory’s Vir Biotechnology VIR Stock Holding History

Vident Investment Advisory’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-84,414
Closed -$1.57M – 1346
2022
Q3 		$1.57M Buy
+84,414
New +$2.15M 0.05% 439

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vident Investment Advisory's VIR Position: Q4 2022 in Review

Vident Investment Advisory sold out of Vir Biotechnology (VIR) in Q4 2022, closing a stake of 84,414 shares — an estimated $1.57M sold.

Vident Investment Advisory first reported a position in VIR in Q3 2022 and held it in 1 quarter. The position peaked at $1.57M in Q3 2022. 224 funds tracked by Wall St. Rank hold VIR as of Q4 2022.

  • Vident Investment Advisory reported no remaining Vir Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 84,414 Vir Biotechnology shares in Q4 2022, an estimated $1.57M.
  • Vident Investment Advisory first reported a position in Vir Biotechnology in Q3 2022 and held it in 1 quarter.
  • Vident Investment Advisory's Vir Biotechnology position peaked at $1.57M in Q3 2022.
  • 224 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2022.

Based on Vident Investment Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.